drugset / Trial / NCT01677390
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Timeline
- Start
- 2012-08
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VORSETUZUMAB MAFODOTIN | Unknown | 1 mg/kg | Intravenous |
| Subject | VORSETUZUMAB MAFODOTIN | Unknown | 2 mg/kg | Intravenous |
| Background | Everolimus | Small molecule | 10 mg | Oral |